2Sandler SR, Karo W, ed. Polymer Syntheses. New York: Academic Press, 1980, 3. 138-161.
3Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA, 1987, 84: 1487-1491.
4Carpenter CP, Woodside MD, Kinkead ER, et al. Response of dogs to repeated intravenous injection of polyethylene glycol 4000. Toxicol Appl Pharmacol, 1971, 18: 35-40.
5Abuchowski A, Davis FF. Soluble Polymer-enzyme adducts. In: Holcenberg JC, Ed. Enzymes as drugs. New York: Wiley and Sons Inc, 1981. 367-383.
6Knauf MJ, Bell DP, Hirtzer P, et al. Relationship of effective molecularsize to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem, 1988, 263: 15064-15070.
7Savoca K, Wieder K. Modified enzymes with unique properties. In: GB Broun, et al. Eds. Enzyme-Polyethylene glycol adducts. Vol 4. New York: Enzyme Engineering, Plenum Press. 1978. 169-173.
8Mur RE. Preliminary clinical results of combination pegylated interferon α-2b plus ribavirin. In: 35th Annual meeting of the European Association for the Study of the liver. 2000, 19.
9Heathcote EJ, Pockros P, Fried M, et al. The pharmacokinetics of pegylated-40 K interferon in chronic hepatitis C patients with cirrhosis. Gastroen-terology, 1999, 116(Pt2): 3190.
10Glue P. Clinical pharmacology of pegylated Interferon α-2b. In: 35th Annual meeting of the European Association for the Study of the Liver. 2000, 13.
